We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings
Read MoreHide Full Article
For the quarter ended March 2024, NeoGenomics (NEO - Free Report) reported revenue of $156.24 million, up 13.9% over the same period last year. EPS came in at -$0.02, compared to -$0.09 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $149.82 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being -$0.03.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how NeoGenomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Clinical - Number of tests performed: 300,827 compared to the 296,176 average estimate based on three analysts.
Clinical - Average revenue/test: $0.45 compared to the $0.43 average estimate based on three analysts.
Revenue- Advanced Diagnostics: $21.71 million versus $21.79 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.9% change.
Revenue- Clinical Services: $134.54 million versus the four-analyst average estimate of $128.18 million. The reported number represents a year-over-year change of +17.1%.
Shares of NeoGenomics have returned -1.1% over the past month versus the Zacks S&P 500 composite's -2.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings
For the quarter ended March 2024, NeoGenomics (NEO - Free Report) reported revenue of $156.24 million, up 13.9% over the same period last year. EPS came in at -$0.02, compared to -$0.09 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $149.82 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being -$0.03.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how NeoGenomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Clinical - Number of tests performed: 300,827 compared to the 296,176 average estimate based on three analysts.
- Clinical - Average revenue/test: $0.45 compared to the $0.43 average estimate based on three analysts.
- Revenue- Advanced Diagnostics: $21.71 million versus $21.79 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.9% change.
- Revenue- Clinical Services: $134.54 million versus the four-analyst average estimate of $128.18 million. The reported number represents a year-over-year change of +17.1%.
View all Key Company Metrics for NeoGenomics here>>>Shares of NeoGenomics have returned -1.1% over the past month versus the Zacks S&P 500 composite's -2.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.